Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation

Early in the SARS-CoV-2 pandemic, there was a high level of optimism based on observational studies and small controlled trials that treating hospitalized patients with convalescent plasma from COVID-19 survivors (CCP) would be an important immunotherapy. However, as more data from controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Rompay, Koen K.A., Olstad, Katherine J., Sammak, Rebecca L., Dutra, Joseph, Watanabe, Jennifer K., Usachenko, Jodie L., Immareddy, Ramya, Roh, Jamin W., Verma, Anil, Shaan Lakshmanappa, Yashavanth, Schmidt, Brian A., Di Germanio, Clara, Rizvi, Nabeela, Stone, Mars, Simmons, Graham, Dumont, Larry J., Allen, A. Mark, Lockwood, Sarah, Pollard, Rachel E., de Assis, Rafael Ramiro, Yee, JoAnn L., Nham, Peter B., Ardeshir, Amir, Deere, Jesse D., Patterson, Jean, Jain, Aarti, Felgner, Philip L., Iyer, Smita S., Hartigan-O’Connor, Dennis J., Busch, Michael P., Reader, J. Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423222/
https://www.ncbi.nlm.nih.gov/pubmed/34494025
http://dx.doi.org/10.1101/2021.09.01.458520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423222/
https://www.ncbi.nlm.nih.gov/pubmed/34494025
http://dx.doi.org/10.1101/2021.09.01.458520

Ejemplares similares